Vinayak G. Wagaskar, MBBS, shares potential explanations for the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—in patients with metastatic castration-resistant prostate cancer (mCRPC). A study presented at the 2021 European Association of Urology showed improved survival outcomes in obese patients with mCRPC compared with overweight and normal weight patients. In the video also discusses next steps with this research.
Wagaskar is an instructor of urology at Mount Sinai in New York City
The management of high-risk localized prostate cancer: Back to the future
April 5th 2024"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.